Immuron Ltd
(ASX: IMC ) Share Price and News
Key Statistics
Introduction to Immuron
Immuron (NDQ: IMRN, ASX: IMC) is an Australian biotech company developing commercial assets that help transform the standard of care for gastrointestinal disorders. IMC has 2 flagship commercial products – Travelan and Protectyn – and 3 clinical-stage assets – IMM-529, IMM-124E and CampETEC.
Travelan and Protectyn are oral immunotherapeutic products. The former helps reduce the risk of traveller's diarrhoea (TD), while the latter is a dietary supplement for gut health that has been formulated to help maintain a healthy digestive function and support the liver.
Both are likely to remain attractive amid concerns related to antibiotic resistance. Immuron’s sales have increased by 136% in FY23 to reach A$1.8m (compared to A$0.8m in FY22). Immuron is also developing clinical stage assets that offer further upside potential for investors.
Future Outlook of Immuron (ASX: IMC)
IMM-124E is the drug substance and the active pharmaceutical ingredient in Travelan. In the U.S., Travelan® is marketed as a dietary supplement for digestive tract protection and as such the company cannot make any claims about the therapeutic benefits against Travellers' diarrhoea. But the company is pursuing a regulatory pathway to license Travelan against travellers’ diarrhoea (Travelan Rx), an indication for which there are no FDA approved drugs for. IMC is conducting a Phase 2 clinical trial in the US with IMM-124E and interim data has been very promising. The company is planning to take it to Phase 3 within the next 12 months.
As for IMM-529 and CampETEC, these are oral formulations intended for patients suffering from recurring Clostridioides Difficile infection and moderate to severe campylobacteriosis respectively. Shareholders can look forward to continued progress with these assets too.
Their strategic positioning in the biopharmaceutical sector, combined with positive travel statistics and a successful Amazon launch, paints an optimistic picture for their continued growth and market expansion.
Is Immuron (ASX: IMC) a Good Stock to Buy?
Immuron Limited emerges as an attractive investment prospect. There are few companies that have both commercial assets with surging sales and clinical stage assets with significant upside.
The company riding the wave of a significant sales surge in its flagship product, Travelan®. There is also upside as the company pursues its clinical ambitions, particularly with IMM-124E. By early 2025, it could well be one of only a handful of ASX biotech stocks with an asset in a Phase 3 trial.
Our Insights on ASX stocks
Sorry, we couldn't find any posts. Please try a different search.
Frequently Asked Questions
Immuron's flagship product is Travelan®, an over-the-counter supplement designed to combat traveler's diarrhea and promote digestive health. Travelan® is clinically proven to reduce gastrointestinal disorders, particularly beneficial for travelers and those with sensitive digestive systems.